WIKIPEDIA, VASHIDONSK
A new therapy designed to treat cancer by regulating gene expression has helped a handful of patients with blood malignancies in a preliminary clinical trial, according to pharmaceutical company OncoEthix. Today (April 7) at the American Association for Cancer Research (AACR) annual meeting in San Diego, California, the Lausanne, Switzerland-based firm presented unpublished data from a Phase I clinical trial of the drug, “OTX015,” a small-molecule inhibitor of the BET-bromodomain proteins BRD2, BRD3, and BRD4, which help to regulate gene expression. Seven of 38 patients for whom sufficient OTX015 trial data were available seemed to have benefited from the drug, OncoEthix announced. Four of those seven patients have acute myelogenous leukemia (AML), while others enrolled in the trial have other hematological malignancies, including diffuse large ...
